- Home
- CARS vs LBRX Comparison
CARS vs LBRX Comparison
Compare CARS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CARS | LBRX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.6M | 602.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CARS | LBRX |
|---|---|---|
| Price | $8.57 | $24.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $17.08 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 859.1K | 183.5K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $723,239,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $45.30 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $8.86 | $13.40 |
| 52 Week High | $13.97 | $25.60 |
Technical Indicators
Market Signals| Indicator | CARS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 19.88 | 54.71 |
| Support Level | N/A | $22.48 |
| Resistance Level | $12.48 | $24.70 |
| Average True Range (ATR) | 0.43 | 1.17 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 8.09 | 49.72 |
Price Performance
Historical ComparisonAbout CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.